ConfirmMDx Genetic Test Identifies Prostate Cancer Aggressiveness

New data confirms that ConfirmMDx, an epigenetic assay, is able to accurately identify prostate cancer aggressiveness. Researchers presented their findings at the European Association of Urology, Section of Urological Research meeting in Glasgow.

The study, co-authored by Sandra M. Gaston, PhD, of the New England Baptist Hospital and Tufts Medical Center in Boston, found that ConfirmMDx was able to strongly correlate with established risk stratification metrics, such as Gleason score and National Comprehensive Cancer Network (NCCN) risk categories.

“Our data demonstrates that ConfirmMDx for Prostate cancer not only provides important diagnostic information to help guide the decision on repeat biopsy, but that genes may also deliver prognostic value,” Dr. Gaston said in a press release.

The test is said to be “highly sensitive” to DNA hypermethylation of three genes that surround prostate cancer: GSTP1, APC, and RASSF1.

“A negative result with the current ConfirmMDx test predicts that a subsequent biopsy will also be negative, identifying the majority of men who may avoid repeat biopsy,” Dr. Gaston said. 


MDxHealth, a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced positive data from an important study confirming the ability of the ConfirmMDx® genes to identify prostate cancer (PCa) aggressiveness in diagnostic biopsies.

The data, presented at the European Association of Urology, Section Urological Research (ESUR) meeting in Glasgow, UK (October 9-11, 2014), confirmed that the epigenetic profile of ConfirmMDx genes generated by the test is strongly correlated with established risk stratification metrics, such as Gleason Score (GS) and the NCCN (National Comprehensive Cancer Network) risk categories.

---